Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 9/20 | 0.72 |
| ▸ | HPGDS | O60760 | 3/20 | 0.65 |
| ▸ | HTR2A | P28223 | 4/20 | 0.54 |
| ▸ | DRD3 | P35462 | 4/20 | 0.54 |
| ▸ | DRD2 | P14416 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18115830 | 0.84 | USP30 (1.00) | USP30HPGDS | |
| SCHEMBL18115827 | 0.84 | USP30 (1.00) | USP30HPGDS | |
| SCHEMBL1908731 | 0.79 | HRH3 (0.48) | USP30HPGDSALDH1A1MAPT | |
| SCHEMBL7679197 | 0.78 | ALDH1A1 (0.66) | USP30HPGDSALDH1A1CYP1A2MAPT | |
| SCHEMBL13449703 | 0.77 | HRH3 (0.47) | USP30HPGDSALDH1A1MAPT | |
| SCHEMBL3801840 | 0.76 | PRMT5 (0.61) | USP30HPGDSHTR2ADRD3DRD2 | |
| SCHEMBL13360509 | 0.76 | ALDH1A1 (0.66) | USP30HPGDSALDH1A1CYP1A2MAPT | |
| SCHEMBL4930304 | 0.76 | ALDH1A1 (0.66) | USP30HPGDSALDH1A1CYP1A2MAPT | |
| SCHEMBL2570318 | 0.76 | ALDH1A1 (0.66) | USP30HPGDSALDH1A1CYP1A2MAPT | |
| SCHEMBL2456362 | 0.75 | USP30 (0.60) | USP30HPGDSHTR2ADRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| EP-2322525-A1 | Purine derivatives for use as adenosin A2A receptor agonists | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
| US-20090240045-A1 | Organic Compounds | NOVARTIS AG | 2009-09-24 | — | — | US | disclosed |
| US-20090240045-A1 | Organic Compounds | NOVARTIS AG | 2009-09-24 | — | — | US | disclosed |
| US-20080242683-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| US-20080242683-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| WO-2007121918-A2 | USE OF 2-(PURIN-9-YL)-TETRAHYDOFURAN-3,4-DIOL DERIVATIVES AS ADENOSINE A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007121920-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242683-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | USP30 3834/4885HPGDS 1420/4885HTR2A 109/4885 |
| US-20100286126-A1 | Organic Compounds | CYP3A43, SLCO1B3, CYP2C19 | USP30 3965/4885HPGDS 3435/4885HTR2A 1769/4885 |
| US-20090240045-A1 | Organic Compounds | CYP3A43, CYP3A4, SLCO1B3 | USP30 3841/4885HPGDS 3773/4885HTR2A 1663/4885 |
| US-20120004212-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | USP30 3965/4885HPGDS 3435/4885HTR2A 1769/4885 |
| US-20120004247-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | USP30 3965/4885HPGDS 3435/4885HTR2A 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.